These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 8459226)

  • 21. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL).
    Wölfel T; Hauer M; Klehmann E; Brichard V; Ackermann B; Knuth A; Boon T; Meyer Zum Büschenfelde KH
    Int J Cancer; 1993 Sep; 55(2):237-44. PubMed ID: 7690346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
    Brichard V; Van Pel A; Wölfel T; Wölfel C; De Plaen E; Lethé B; Coulie P; Boon T
    J Exp Med; 1993 Aug; 178(2):489-95. PubMed ID: 8340755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
    Bakker AB; Schreurs MW; de Boer AJ; Kawakami Y; Rosenberg SA; Adema GJ; Figdor CG
    J Exp Med; 1994 Mar; 179(3):1005-9. PubMed ID: 8113668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes.
    Mazzocchi A; Storkus WJ; Traversari C; Tarsini P; Maeurer MJ; Rivoltini L; Vegetti C; Belli F; Anichini A; Parmiani G; Castelli C
    J Immunol; 1996 Oct; 157(7):3030-8. PubMed ID: 8816412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.
    Kan-Mitchell J; Huang XQ; Steinman L; Oksenberg JR; Harel W; Parker JW; Goedegebuure PS; Darrow TL; Mitchell MS
    Cancer Immunol Immunother; 1993 Jul; 37(1):15-25. PubMed ID: 8513449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melanoma cell lysis by human CTL clones: differential involvement of T3, T8 and HLA antigens.
    Fossati G; Anichini A; Parmiani G
    Int J Cancer; 1987 Jun; 39(6):689-94. PubMed ID: 3108167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.
    Anichini A; Mazzocchi A; Fossati G; Parmiani G
    J Immunol; 1989 May; 142(10):3692-701. PubMed ID: 2469723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
    Rivoltini L; Barracchini KC; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo NP; Topalian SL; Simonis TB; Rosenberg SA
    Cancer Res; 1995 Jul; 55(14):3149-57. PubMed ID: 7541714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
    Takahashi T; Irie RF; Nishinaka Y; Hoon DS
    Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
    González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
    Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
    Coulie PG; Brichard V; Van Pel A; Wölfel T; Schneider J; Traversari C; Mattei S; De Plaen E; Lurquin C; Szikora JP; Renauld JC; Boon T
    J Exp Med; 1994 Jul; 180(1):35-42. PubMed ID: 8006593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
    Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
    Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
    Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
    Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients.
    Takahashi T; Irie RF; Morton DL; Hoon DS
    Cell Immunol; 1997 Jun; 178(2):162-71. PubMed ID: 9225007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines.
    Dufour E; Carcelain G; Gaudin C; Flament C; Avril MF; Faure F
    J Immunol; 1997 Apr; 158(8):3787-95. PubMed ID: 9103444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
    Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.